FTC Says Ex‑‘Pharma Bro’ Breached Lifetime Ban by Trading Pharma Stocks

The Federal Trade Commission has lodged a complaint asserting that Martin Shkreli, the ex‑pharmaceutical executive infamous for his contentious pricing tactics, has been purchasing and divesting shares of firms that develop or sell medicines, a conduct that may breach his lifetime industry ban.

Shkreli, who acquired the moniker “Pharma Bro” following a widely publicized incident over the price of the antiparasitic medication Daraprim, was placed under a lifetime ban by the FTC several years prior after investigators determined he had participated in illegal marketing and additional wrongdoing.

According to the latest FTC filing, despite the prohibition, Shkreli has remained active in equities, carrying out trades across a variety of pharmaceutical companies. The commission says it uncovered the activity by examining trading logs that reveal repeated buys and sells of shares tied to drug development and distribution.

Regulators explain that the ban was designed to keep Shkreli from shaping the pharmaceutical arena, and any violation erodes the FTC’s enforcement power. Breaching a lifetime prohibition could subject him to civil fines, injunctions and potentially additional criminal referrals.

Legal analysts point out that the FTC may pursue monetary penalties and an order prohibiting Shkreli from any future participation in pharmaceutical‑related securities. The agency could also forward the case to the Department of Justice should it deem criminal conduct present.

Thus far, Shkreli has offered no public comment on the accusations, and his lawyers have signaled their intention to challenge the commission’s allegations.

The lawsuit underscores the difficulties regulators encounter when overseeing adherence to long‑term bans, particularly as some individuals turn to financial markets to preserve influence.

Watchers will be attentive to the upcoming court hearing on the FTC’s complaint, which may establish precedent for the vigor with which lifetime bans are enforced in biotech and pharmaceutical sectors.